{"id":56043,"date":"2026-02-02T18:49:49","date_gmt":"2026-02-02T10:49:49","guid":{"rendered":"https:\/\/flcube.com\/?p=56043"},"modified":"2026-02-02T18:49:50","modified_gmt":"2026-02-02T10:49:50","slug":"jj-akeega-gets-chmp-nod-for-brca-mutated-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56043","title":{"rendered":"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer"},"content":{"rendered":"\n<p><strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE:\u202fJNJ<\/a>) announced that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the <strong>European Medicines Agency (EMA)<\/strong> has recommended approval for an expanded indication of <strong>AKEEGA (niraparib\u2011abiraterone)<\/strong> in combination with <strong>prednisone\/prednisolone (AAP)<\/strong> and <strong>androgen deprivation therapy (ADT)<\/strong> for patients with <strong>BRCA1\/2 mutations (germline and\/or somatic)<\/strong> in <strong>metastatic hormone\u2011sensitive prostate cancer (mHSPC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-clinical-basis\">Regulatory Milestone &amp; Clinical Basis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Johnson &amp; Johnson (NYSE:\u202fJNJ)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>AKEEGA (niraparib\u2011abiraterone)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>Prednisone\/prednisolone (AAP) + Androgen deprivation therapy (ADT)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>mHSPC with BRCA1\/2 mutations (germline\/somatic)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>CHMP of EMA<\/td><\/tr><tr><td><strong>Recommendation<\/strong><\/td><td>Positive opinion for expanded indication<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>AMPLITUDE study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-amplitude-study-key-efficacy-data\">AMPLITUDE Study Key Efficacy Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Niraparib\/AAP Group<\/th><th>Control Group<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Radiographic PFS (rPFS)<\/strong><\/td><td>Not reached<\/td><td>26 months<\/td><td>Risk reduction <strong>48%<\/strong> (P\u202f&lt;\u202f0.0001)<\/td><\/tr><tr><td><strong>Time to Disease Progression<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td>Extended by <strong>56%<\/strong> (P\u202f&lt;\u202f0.0001)<\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>Early trend<\/td><td>\u2014<\/td><td>Death risk reduced <strong>25%<\/strong> (data immature, follow\u2011up ongoing)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile\">Safety Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Consistency:<\/strong> Safety profile in mHSPC consistent with approved mCRPC indication<\/li>\n\n\n\n<li><strong>Most Common Grade\u202f3\/4 AEs:<\/strong> Anemia and hypertension<\/li>\n\n\n\n<li><strong>Discontinuation Rate:<\/strong> Low discontinuation due to adverse events<\/li>\n\n\n\n<li><strong>Manageability:<\/strong> AEs manageable through dose adjustments and supportive care<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prostate Cancer Market:<\/strong> EU mHSPC market valued at <strong>$1.2\u202fbillion<\/strong> : 2025; BRCA\u2011mutated subset represents <strong>~10\u201315%<\/strong> : of patients<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> First PARP inhibitor + AR pathway combination in BRCA\u2011mutated mHSPC; differentiates from standard AR\u2011targeted therapy alone<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u20ac300\u2013500\u202fmillion<\/strong> : peak annual EU sales for AKEEGA in expanded indication by 2028<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens J&amp;J\u2019s prostate cancer franchise following <strong>Erleada<\/strong> success; validates combination approach in earlier disease stage<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> European Commission decision expected <strong>Q2\u202f2026<\/strong>; potential US FDA filing under evaluation<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approval timelines, commercial expectations, and revenue projections for AKEEGA. Actual results may differ due to EC review outcomes, competitive dynamics, and market access negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56044,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,149,858],"class_list":["post-56043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for an expanded indication of AKEEGA (niraparib\u2011abiraterone) in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT) for patients with BRCA1\/2 mutations (germline and\/or somatic) in metastatic hormone\u2011sensitive prostate cancer (mHSPC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56043\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for an expanded indication of AKEEGA (niraparib\u2011abiraterone) in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT) for patients with BRCA1\/2 mutations (germline and\/or somatic) in metastatic hormone\u2011sensitive prostate cancer (mHSPC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56043\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T10:49:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T10:49:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer\",\"datePublished\":\"2026-02-02T10:49:49+00:00\",\"dateModified\":\"2026-02-02T10:49:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043\"},\"wordCount\":326,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0206.webp\",\"keywords\":[\"Cancer\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56043#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56043\",\"name\":\"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0206.webp\",\"datePublished\":\"2026-02-02T10:49:49+00:00\",\"dateModified\":\"2026-02-02T10:49:50+00:00\",\"description\":\"Johnson & Johnson (NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for an expanded indication of AKEEGA (niraparib\u2011abiraterone) in combination with prednisone\\\/prednisolone (AAP) and androgen deprivation therapy (ADT) for patients with BRCA1\\\/2 mutations (germline and\\\/or somatic) in metastatic hormone\u2011sensitive prostate cancer (mHSPC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56043\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0206.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0206.webp\",\"width\":1080,\"height\":608,\"caption\":\"J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56043#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for an expanded indication of AKEEGA (niraparib\u2011abiraterone) in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT) for patients with BRCA1\/2 mutations (germline and\/or somatic) in metastatic hormone\u2011sensitive prostate cancer (mHSPC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56043","og_locale":"en_US","og_type":"article","og_title":"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer","og_description":"Johnson & Johnson (NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for an expanded indication of AKEEGA (niraparib\u2011abiraterone) in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT) for patients with BRCA1\/2 mutations (germline and\/or somatic) in metastatic hormone\u2011sensitive prostate cancer (mHSPC).","og_url":"https:\/\/flcube.com\/?p=56043","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-02T10:49:49+00:00","article_modified_time":"2026-02-02T10:49:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56043#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56043"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer","datePublished":"2026-02-02T10:49:49+00:00","dateModified":"2026-02-02T10:49:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56043"},"wordCount":326,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56043#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp","keywords":["Cancer","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56043#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56043","url":"https:\/\/flcube.com\/?p=56043","name":"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56043#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56043#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp","datePublished":"2026-02-02T10:49:49+00:00","dateModified":"2026-02-02T10:49:50+00:00","description":"Johnson & Johnson (NYSE:\u202fJNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for an expanded indication of AKEEGA (niraparib\u2011abiraterone) in combination with prednisone\/prednisolone (AAP) and androgen deprivation therapy (ADT) for patients with BRCA1\/2 mutations (germline and\/or somatic) in metastatic hormone\u2011sensitive prostate cancer (mHSPC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56043#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56043"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56043#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp","width":1080,"height":608,"caption":"J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56043#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0206.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56043"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56043\/revisions"}],"predecessor-version":[{"id":56045,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56043\/revisions\/56045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56044"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}